

Wisner Baum is currently investigating claims involving AngioDynamics and its subsidiary, Navilyst Medical, regarding implantable port catheter devices. Patients who have experienced serious complications involving one of these devices may qualify for a free, confidential case evaluation. Call us at (310) 207-3233 to discuss your legal options.
July 2026: AngioDynamics Port Catheter MDL Grows to 401 Pending Actions
As of July 1, 2026, there are 401 pending actions in MDL 3125 - IN RE: AngioDynamics, Inc., and Navilyst Medical, Inc., Port Catheter Products Liability Litigation. Plaintiffs joining the litigation continue to allege injuries such as infection, thrombosis, and device fracture or migration.
June 2026: AngioDynamics Port Catheter MDL Reaches 391 Pending Actions
According to the latest JPML report, there are 391 pending actions in MDL 3125 - IN RE: AngioDynamics, Inc., and Navilyst Medical, Inc., Port Catheter Products Liability Litigation as of June 1, 2026.
May 2026: AngioDynamics Port Catheter MDL Grows to 375 Pending Actions
There are currently 375 pending actions in MDL 3125 - IN RE: AngioDynamics, Inc., and Navilyst Medical, Inc., Port Catheter Products Liability Litigation.
In October 2024, the Judicial Panel on Multidistrict Litigation ordered the then-pending cases to be centralized in the Southern District of California and assigned them to the Honorable Jinsook Ohta. At the time of the order, there were 56 cases pending across 28 districts.
April 2026: Hundreds of Adverse Event Reports Filed Related to AngioDynamics Port Catheters
Over the past six years, the U.S. Food and Drug Administration has received hundreds of adverse event reports related to Port Catheters manufactured by AngioDynamics and its subsidiary, Navilyst Medical, through its MAUDE database.
Reports include infections, swelling, pulmonary embolisms, and other serious injuries alleged by patients. Some reports also indicate that the ports had migrated or fractured, causing additional harm.
March 2026: Bellwether Trial Selections Expected in AngioDynamics Port Catheter MDL
As pretrial motions continue in the AngioDynamics Port Catheter MDL, each side is expected to present its selections for bellwether trials. The selected cases are expected to represent a wide range of commonly reported complications, including infection, thrombosis, and device fracture.
February 2026: AngioDynamics Port Catheter MDL Grows to 317 Pending Actions
The multidistrict litigation pending out of the Southern District of California has grown to 317 actions. The number of pending actions in the MDL is updated each month. It is expected that the number of claims may continue to increase in the coming months as additional patients who potentially suffered complications or injuries related to their AngioDynamics smart ports come forward.
January 2026: Legal Complaints Filed Nationwide Against AngioDynamics
Legal complaints have been filed nationwide against AngioDynamics and Navilyst Medical. These documents allege that the SmartPort manufacturer knew or should have known about the potential for harm associated with the device's use and failed to warn consumers.
AngioDynamics (Nasdaq: ANGO) is a medical device manufacturer founded in Queensbury, New York, in 1988 and headquartered in Latham, New York. It built much of its vascular access business through acquisition, most significantly its 2012 purchase of Navilyst Medical, which remains a subsidiary and whose name still appears on many of the devices named in the current litigation.
The company makes a range of implantable port catheters: small devices placed under the skin and connected to a vein so clinicians can reach the bloodstream repeatedly over months or years. They are used to deliver chemotherapy, antibiotics, and other IV medications and to draw blood without constant needle sticks. AngioDynamics sells them under several brands — including the SmartPort, Vortex, Xcela Plus, and BioFlo lines — alongside the NMI Port and LifePort lines produced by Navilyst.
AngioDynamics manufactures a wide range of implantable ports under the SmartPort line. The SmartPort family of port catheters is one of the most commonly used and is frequently implanted for the delivery of chemotherapy and other long-term IV treatments.
SmartPort family of port catheters:
In May 2020, AngioDynamics received FDA clearance to market the SmartPort+ and SmartPort Plastic Implantable Ports.
AngioDynamics manufactures a line of catheters under the Vortex brand name. This family of catheters is also used for chemotherapy and other long-term IV treatments.
Vortex Port family products:
In June 2013, AngioDynamics announced it had received FDA clearance for its Xcela Plus Port family with Pressure Activated Safety Valve. The port was marketed as the “first proximally-valved CT port.” It is used for the same general purposes as the Smartport and Vortex devices, including for chemotherapy and other medicines requiring long-term vascular access.
The BioFlo port is another manufactured by AngioDynamics. The implantable port is used for long-term IV access during chemotherapy and other treatments. Along with the others, it has been mentioned in lawsuits filed nationwide. Patients allege it contains a design defect that was not adequately disclosed to consumers and caused serious injury or other harm.
Navilyst, a subsidiary of AngioDynamics, manufactures its own lines of port catheters, including the NMI Port and LifePort lines. Patients who received a Navilyst NMI Port or LifePort may still be able to take legal action against the manufacturer and may qualify to join the existing multidistrict litigation pending in the Southern District of California.
Lawsuits have been filed across the country against AngioDynamics and Navilyst Medical, alleging their port catheters may cause serious harm, and the potential of harm was not adequately disclosed to consumers. Reported injuries range in severity, but some have required revision or removal surgery. Individuals who suffer new or worsening symptoms are encouraged to act quickly to ensure prompt diagnosis and treatment. Conditions related to a part of the catheter can escalate quickly, causing additional harm.
Alleged injuries reported in the AngioDynamics port catheter lawsuit:
AngioDynamics port catheters are designed for long-term vascular access. They are implanted inside the body and may remain in place for several months to a year or more.
The catheter portion (the thin tube that runs into a vein near the heart) must withstand constant pressure, exposure to blood, and other factors that may cause it to break down. The surface of the tube itself may become pitted and rough as it degrades over time. As decay progresses, the catheter may become more prone to migration, fracture, or failure, which can lead to infection or other complications. The potential for this breakdown has become a central issue in lawsuits filed nationwide.
The tube portion of an AngioDynamics catheter is made of a flexible plastic called polyurethane. It also has barium sulfate mixed in. The barium sulfate helps the tube appear on X-rays, so doctors can confirm whether it is properly placed.
How well the mixture holds up depends on the barium sulfate-to-plastic ratio and whether it was properly blended. A properly functioning catheter should remain flexible and able to handle medications and maintain steady blood flow. Plaintiffs allege that the tube on their port catheters may be prone to migration or fracture.
One potential problem with port catheters is surface degradation. Studies suggest that exposure to the bloodstream may cause catheters to break down. Over time, this breakdown may cause barium sulfate particles to be released from the catheter surface, resulting in the catheter becoming rough or pitted. These rough surfaces make it easier for bacteria to adhere to and cause infections. The tube also may become thinner as the surface wears, making it more prone to fracture.
When the catheter surface is no longer smooth due to degradation, bacteria can settle and form a biofilm. This thin layer of bacteria is sealed under a protective coating, making it challenging for the body’s immune system or antibiotics to reach. A 2024 study found that roughly 60 to 70% of nosocomial infections were attributed to biofilms.
A catheter that has begun to degrade may have weak spots that make it more likely to crack or break, particularly when it is under pressure from power injections. Power injections are high-pressure contrast injections used for CT scans and are frequently used for catheter patients. AngioDynamics and Navilyst port catheters are cleared for CT scans.
Lawsuits allege that patients may have experienced device cracking, fracture, and migration. Claims include that pieces of these devices may have traveled through the bloodstream into the heart or lungs, causing serious and potentially life-threatening complications. Patients have also reported that the tube may separate from the port itself, causing significant harm.
AngioDynamics has issued two recalls on its port catheter lines, including the Vortex and SmartPort families. These recalls were related to sterility and labeling issues. Neither recall was related to the injuries alleged in the current litigation.
On February 22, 2021, AngioDynamics (Navilyst Medical, Inc) initiated a recall on specific batches of its SmartPort CT-Implantable Port. The class II recall noted that these devices may have compromised sterility and could be susceptible to failure. The recall involved 267 kits and was terminated on July 19, 2022.
On September 20, 2022, a class II recall was issued for 11 units of AngioDynamics Vortex MP Port Titanium Low Profile Implanted Port. The recall was the result of a labeling issue (as opposed to a design or manufacturing defect). It was determined that the printed instructions for use were not shipped with the device.
Many port catheter patients are unaware of what kind of device they have implanted or who manufactured it. Medical records should indicate or identify the product name and its manufacturer. Documents such as an operative report, implant card, or device sticker, along with the hospital discharge summary, may contain information that can help identify the type and manufacturer of the port.
Patients should look for qualifying port catheters, which may include:
The manufacturer of the device may be noted as AngioDynamics, Navilyst Medical, or Navilyst. For patients who are unable to access these records, an attorney may be able to help. Lawsuits have been filed against several port catheter manufacturers. Individuals who have suffered catheter-related complications are encouraged to research whether they may qualify to take legal action.
Multiple MDLs are now pending against manufacturers of port catheters, including AngioDynamics (MDL 3125) and Bard PowerPort (MDL 3081). The AngioDynamics MDL has been centralized before Judge Ohta in the Southern District of California. It has hundreds of pending actions and is in its early stages.
The Bard PowerPort MDL is much larger, with over 3,100 pending actions. It is being heard by Judge David G. Campbell in the District of Arizona. Litigation is further along, with bellwether trials beginning in 2026.
While each of these litigations involves overlapping theories of design defect and failure to warn, they are entirely separate. Individuals who suffered complications related to their port catheters are encouraged to contact Wisner Baum to schedule a free, confidential consultation to determine their eligibility for taking legal action.
Multiple legal claims have been made against AngioDynamics and Navilyst. These theories allege that their port catheters contained dangerous design and manufacturing defects that could have caused severe harm to patients throughout the country.
Legal documents allege that AngioDynamics and its subsidiary, Navilyst Medical, were negligent in failing to exercise reasonable care in the design, testing, manufacturing, and post-market surveillance of their port catheter devices.
It is alleged that the SmartPort family and other product lines manufactured by AngioDynamics and Navilyst Medical contained a design defect that made them unsafe. Patients allege that the devices’ design was unreasonably dangerous and that safer alternative designs existed.
Legal documents further allege that the devices contain a dangerous manufacturing defect. Manufacturing defects occur during the production process and cause a product to deviate from its original design.
Allegations against AngioDynamics and Navilyst include that they failed to adequately warn patients and providers about the known risks of harm associated with the use of their devices.
Patients allege the devices were not fit for their intended use and failed to perform as warranted, thereby breaching express and implied warranties guaranteed by the manufacturer.
Complaints filed against the manufacturers argue that the companies knew about material safety risks associated with their products and intentionally or negligently concealed them from patients and providers.
Individuals who suffered complications or other harm related to their AngioDynamics or Navilyst port catheter may be eligible to file a lawsuit. Eligibility depends on the device that was implanted, the nature and severity of the injury or complications, the timing between the implant and injury, and any applicable statutes of limitations. It is important to note that not all port catheter patients will qualify, even if they suffered an adverse complication after implantation.
Patients may qualify for an AngioDynamics port catheter lawsuit if they:
Family members of patients who have died from a catheter-related complication may also be eligible to take legal action through a wrongful death claim and are encouraged to consult with an attorney as soon as possible.
Individuals who believe that their AngioDynamics port catheter caused them harm are encouraged to seek medical attention immediately. Prompt diagnosis and treatment are often critical to a successful medical outcome. If they qualify, patients may be eligible to file a lawsuit against the manufacturer and should follow the steps below to determine whether they qualify.
Steps to take if you believe an AngioDynamics port catheter caused harm:
At Wisner Baum, we understand how hard it can be to deal with a catheter-related complication. Our firm has helped thousands of families across the country seek justice against medical device manufacturers that have acted intentionally or negligently. We can help determine whether you, too, may qualify for a lawsuit. Contact our office now to schedule a free, confidential case evaluation.
Our firm has extensive experience with medical device product liability claims and will not hesitate to hold corporations nationwide accountable for their wrongdoing. Call Wisner Baum at (310) 207-3233 or visit us online to schedule a consultation with one of our defective medical device lawyers.
"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.
The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
$289.2 million jury verdict in Monsanto Roundup trial
Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.
Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.
Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
Yes, hundreds of lawsuits have been filed nationwide against AngioDynamics and its subsidiary Navilyst Medical. These lawsuits allege that their port catheters contain dangerous design and manufacturing defects and that the companies allegedly knew about the risk of harm associated with using their devices and failed to warn consumers.
Yes, AngioDynamics has previously recalled at least two of its port catheter product lines, including SmartPorts and several units of the Vortex family. The SmartPort recall was related to a sterility issue, and the Vortex recall was due to a labeling error. Even without a recall, patients may still have grounds for legal action.
Many patients are unaware of the type of port catheter they have implanted or who manufactured it. The best way to identify the manufacturer is through medical documents, such as the hospital discharge summary. If you are unable to determine who manufactured the device, an attorney may be able to assist.
While not all AngioDynamics port catheter lawsuits will go to trial, several bellwether trials are expected to be selected from the MDL currently pending in the Southern District of California.
Wisner Baum is continuing to investigate claims related to AngioDynamics port catheters. Patients are encouraged to contact the firm to determine if they may be eligible to file a lawsuit.